COMPANY PROFILE

GAMAMABS PHARMA

Explore full profile

Develops innovative monoclonal antibodies against cancer

Toulouse, FranceFounded 2013Biotech & Life Sciences

Valuation $50–100M Last recorded · 2015

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About GAMAMABS PHARMA

GamaMabs Pharma is a clinical stage immuno-oncology company focused on developing optimized therapeutic antibodies for the treatment of cancer. The company specializes in creating low fucose antibodies, which have enhanced tumor cell killing properties by activating immune system cells. GamaMabs operates primarily in the biotechnology and pharmaceutical markets, targeting healthcare providers and institutions involved in cancer treatment and research. The business model revolves around the development and licensing of its proprietary antibody technologies. GamaMabs has a significant licensing agreement with MedImmune USA to develop an Antibody Drug Conjugate aimed at targeting cancer. Revenue is generated through licensing agreements, partnerships, and potentially future sales of approved therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Closed
Founded: 2013
Headquarters: Toulouse, France
Employees: 7
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, participations bpifrance, observatoire industrial tech, DT and LS, observatoire healthtech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Dec 2015	$17M	$66M	iXO Private Equity · Andera Partners · Bpifrance · Alto Invest	—
SERIES A✓Equity / VC	Sep 2013	$3.4M	$14M	LFB · Bpifrance · iXO Private Equity	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

GAMAMABS PHARMA website traffic

Latest recorded traffic for GAMAMABS PHARMA is 20 monthly website visits, down 95.7% over the last three months. GAMAMABS PHARMA's team grew 0% over the past year.

Latest monthly visits20 3-month web change-95.7% 1-year team growth0%

Monthly website visitsJun 2015–Apr 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CECellectisDeveloping allogeneic CAR-T cells	Paris, France	Operational	241	$19M	$248M
MPMaaT PharmaDevelops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments	Lyon, France	Operational
ETEgle TherapeuticsEgle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones	Paris, France	Operational
CTCyllene TherapeuticsNon-replicating HSV-1 gene therapy for neurological diseases.	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
OBOne BiosciencesOperating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases	Paris, France	Operational
ATApmonia TherapeuticsApmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies	Reims, France	Operational
HBHoning BiosciencesBio-therapeutics company that develops and improves cell-based therapies	Paris, France	Operational